2348 — Dawnrays Pharmaceutical (Holdings) Share Price
0.000.00%
Last trade - 00:00- HK$1.76bn
- HK$343.19m
- CNY1.06bn
- 70
- 93
- 77
- 94
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.49 | ||
| Price to Tang. Book | 0.59 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.54 | ||
| EV to EBITDA | 0.43 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 18.65% | ||
| Return on Equity | 18.29% | ||
| Operating Margin | 60.76% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 1,024.27 | 1,165.15 | 1,277.68 | 1,151.14 | 1,060.31 | n/a | n/a | 2.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +5.4 | +14.75 | +8.36 | -0.12 | -3.53 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dawnrays Pharmaceutical (Holdings) Limited is an investment holding company principally engaged in the development, manufacture and sale of non-patented pharmaceutical medicines. The products include intermediate pharmaceutical, bulk medicines and finished drugs. The Company operates its business through two segments. The Intermediates and Bulk Medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines. The Finished Drugs segment is engaged in the manufacture and sale of finished drugs, including antibiotics finished drugs and non-antibiotics finished drugs.
Directors
- Shaojun Chen CEO (40)
- Yung Lai Hung EDR (70)
- Tung Ming Li EDR (66)
- Kit Ling Pang SEC
- Bo Hui DRC (36)
- Hong Man Leung NED (40)
- Hao Xi Ede NID (62)
- Ming Yee Lam NID (50)
- Tung Sing Lo NID (46)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 20th, 2002
- Public Since
- July 11th, 2003
- No. of Employees
- 1,183
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,501,893,000
- Address
- Units 3001-02, 30/F, CNT Tower, Wanchai
- Web
- https://www.dawnrays.com/
- Phone
- +852 null21119708
- Auditors
- Ernst & Young
Upcoming Events for 2348
Dawnrays Pharmaceutical (Holdings) Ltd Annual Shareholders Meeting
Dividend For 2348.HK - 0.0320 HKD
Dividend For 2348.HK - 0.0480 HKD
Similar to 2348
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
What is the Dawnrays Pharmaceutical (Holdings) share price?
As of Today at 20:12 UTC, shares in Dawnrays Pharmaceutical (Holdings) are trading at HK$1.16. This share price information is delayed by 15 minutes.
How has the Dawnrays Pharmaceutical (Holdings) share price performed this year?
Shares in Dawnrays Pharmaceutical (Holdings) last closed at HK$1.16 and the price had moved by -0.85% over the past 365 days. In terms of relative price strength the Dawnrays Pharmaceutical (Holdings) share price has outperformed the FTSE Developed Asia Pacific Index by +0.28% over the past year.
What are the analyst and broker recommendations for Dawnrays Pharmaceutical (Holdings)?
The overall consensus recommendation for Dawnrays Pharmaceutical (Holdings) is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Dawnrays Pharmaceutical (Holdings) dividend yield?
Dawnrays Pharmaceutical (Holdings) does not currently pay a dividend.
Does Dawnrays Pharmaceutical (Holdings) pay a dividend?
Dawnrays Pharmaceutical (Holdings) does not currently pay a dividend.
When does Dawnrays Pharmaceutical (Holdings) next pay dividends?
Dawnrays Pharmaceutical (Holdings) does not currently pay a dividend.
How do I buy Dawnrays Pharmaceutical (Holdings) shares?
To buy shares in Dawnrays Pharmaceutical (Holdings) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Dawnrays Pharmaceutical (Holdings)?
As of the previous close price of HK$1.16, shares in Dawnrays Pharmaceutical (Holdings) had a market capitalisation of HK$1.76bn.
Where are Dawnrays Pharmaceutical (Holdings) shares listed?
Here are the trading details for Dawnrays Pharmaceutical (Holdings):
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2348
What kind of share is Dawnrays Pharmaceutical (Holdings)?
Based on an overall assessment of its quality, value and momentum Dawnrays Pharmaceutical (Holdings) is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Dawnrays Pharmaceutical (Holdings) share price forecast for 2025?
The analyst consensus target price for shares in Dawnrays Pharmaceutical (Holdings) is HK$2.92. That is 152.04% above the last closing price of HK$1.16.
Analysts covering Dawnrays Pharmaceutical (Holdings) currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Dawnrays Pharmaceutical (Holdings) share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dawnrays Pharmaceutical (Holdings). Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -0.87%.
As of the last closing price of HK$1.16, shares in Dawnrays Pharmaceutical (Holdings) were trading -2.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Dawnrays Pharmaceutical (Holdings) PE Ratio?
The Dawnrays Pharmaceutical (Holdings) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$1.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Dawnrays Pharmaceutical (Holdings)?
Dawnrays Pharmaceutical (Holdings)'s management team is headed by:
- Shaojun Chen - CEO
- Yung Lai Hung - EDR
- Tung Ming Li - EDR
- Kit Ling Pang - SEC
- Bo Hui - DRC
- Hong Man Leung - NED
- Hao Xi Ede - NID
- Ming Yee Lam - NID
- Tung Sing Lo - NID